Varicella-Zoster Virus: Aspects of Pathogenesis and Host Response to Natural Infection and Varicella Vaccine

Advances in Virus Research

Volumn 46, Issue C, 1996, Pages 263-309

  Arvin, Ann M ^a   Moffat, Jennifer F ^a   Redman, Rebecca ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030066246     PISSN: 00653527     EISSN: 15578399     Source Type: Book Series    
DOI: 10.1016/S0065-3527(08)60074-3     Document Type: Article

References (75)

1. 1995 American Academy of Pediatrics, Recommendations for the use of varicella vaccine. Pediatrics 95 (1995), 791–796.
2. Arbeter, A.M., Starr, S.E., Weibel, R.E., Plotkin, S.A., Varicella vaccine studies in healthy children and adults. Pediatrics, 78(Suppl.), 1986, 748 756.
3. Arvin, A.M., Cell-mediated immunity to varicella-zoster virus. J. Infect. Dis. 166:Suppl. 1 (1992), 35–41.
4. Arvin, A.M., Varicella-zoster virus. Fields, B.N., et al. (eds.) ‘Virology” 3rd Ed., 1995, Raven, New York in press.
5. Arvin, A.M., Koropchak, C.M., Wittek, A.E., Immunologic evidence of reinfection with varicella-zoster virus. J. Infect. Dis. 148 (1983), 200–205.
6. Arvin, A.M., Kinney-Thomas, E., Shriver, K., Grose, C., Koropchak, C.M., Scranton, E., Wittek, A.E., Diaz, P.S., Immunity to varicella-zoster viral glycoproteins, gp I (90/58) and gp III (gp 118) and to a nonglycosylated protein, p170. J. Immunol. 137 (1986), 1346–1351.
7. Arvin, A.M., Koropchak, C.M., Williams, B.R.G., Grumet, F.C., Foung, S.K., Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J. Infect. Dis. 154 (1986), 422–429.
8. Arvin, A.M., Solem, S.M., Koropchak, C.M., Kinney-Thomas, E., Paryani, S.G., Humoral and cellular immunity to varicella-zoster virus glycoprotein, gp I, and to a non-glycosylated protein, p170, in the strain 2 guinea pig. J. Gen. Virol. 68 (1987), 2449–2454.
9. +phenotype. J. Immunol. 146 (1991), 257–264.
10. Asano, Y., Nakayama, H., Yazaki, T., et al. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatric. 59 (1977), 3–7.
11. Asano, Y., Itakura, N., Hiroishi, Y., et al. Viral replication and immunologic responses in children naturally infected with varicella-zoster and in varicella vaccine recipients. J. Infect. Dis. 152 (1985), 863–868.
12. Bergen, R.E., Diaz, P.S., Arvin, A.M., The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J. Infect. Dis. 162 (1990), 1049–1054.
13. Bergen, R.E., Sharp, M., Sanchez, A., Judd, A.K., Arvin, A.M., Human T-cells recognize multiple eptiopes of a major tegument/immediate early protein (IE62) and glycoprotein I of varicella-zoster virus. Viral Immunol. 4 (1991), 151–166.
14. Bowden, R.A., Levin, M.S., Giller, R.H., Tubergen, D.G., Hayward, A.R., Lysis of varicella zoster virus infected cells by lymphocytes from normal humans and immunosuppressed pediatric leukaemic patients. Clin. Exp. Immunol. 60 (1985), 387–395.
15. Cohen, J.I., Straus, S.E., Varicella-zoster virus and its replication. Fields, B.N., et al. (eds.) ‘Virology” 3rd Ed., 1995, Raven, New York in press.
16. Connelly, B.L., Stanberry, L.R., Bernstein, D.I., Detection of varicella-zoster virus DNA in nasopharyngeal secretions of immune household contacts of varicella. J. Infect. Dis. 168 (1993), 1253–1255.
17. Croen, K., Straus, S., Varicella-zoster virus latency. Annu. Rev. Microbiol. 4 (1991), 265–282.
18. Croen, K., Ostrove, J., Dragovic, L., Straus, S., Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses. Proc. Natl. Acad. Sci. U.S.A. 85 (1988), 9773–9777.
19. Cunningham, A.L., Turner, R.R., Miller, A.C., Para, M.F., Merigan, T.C., Evolution of recurrent herpes simplex virus lesions. An immunohistologic study. J. Clin. Invest., 75, 1985, 226.
20. Davison, A.J., Scott, J.E., The complete DNA sequence of varicella zoster virus. J. Gen. Virol. 67 (1986), 597–611.
21. Davison, A.J., Edson, C.M., Ellis, R.W., Forghani, B., Gilden, D., Grose, C., Keller, P.M., Vafai, A., Wroblewska, Z., Yamanishi, K., A new nomenclature for the glycoprotein genes of varicella-zoster virus and their glycosylated products. J. Virol. 57 (1986), 1195–1197.
22. Diaz, P.S., Smith, S., Hunter, E., Arvin, A.M., Immunity to varicella-zoster virus antigen, glycoprotein I (gp I) and a non-glycosylated protein (p 170): Relation to the immunizing regimen of live attenuated varicella vaccine. J. Infect. Dis. 158 (1988), 1245–1252.
23. Diaz, P.S., Hunter, E.L., Smith, S.M., Arvin, A.M., T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J. Immunol. 142 (1989), 636–641.
24. Feldman, S., Epp, E., Isolation of varicella-zoster virus from blood. J. Pediatr. 88 (1976), 265–268.
25. Forman, S.J., Nocker, P., Gallagher, M., Zaia, J., Wright, C., Bolen, J., Mills, B., Hecht, T., Pattern of T cell reconstitution following allogenic bone marrow transplantation for acute hematological malignancy. Transplantatio. 34 (1982), 96–98.
26. Gabel, C.A., Dubey, L., Steinberg, S.P., Sherman, D., Gershon, M.D., Gershon, A.A., Varicella-zoster virus glycoprotein oligosaccharides are phosphorylated during posttranslational maturation. J. Virol. 63 (1989), 4264–4276.
27. Gershon, A.A., Varicella vaccine: The American experience. J. Infect. Dis. 166:Suppl. 1 (1992), 63–68.
28. Gershon, A.A., Steinberg, S.P., Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N. Eng. J. Med. 320 (1989), 892–897.
29. Gershon, A.A., Steinberg, S.P., Gelb, L., And the NIAID Collaborative Varicella Vaccine Study Group. Live attenuated varicella vaccine: Efficacy for children with leukemia in remission. JAMA, J. Am. Med. Assoc. 252 (1984), 355–362.
30. Giller, R.H., Bowden, R.A., Levin, M.J., Walker, L.J., Tubergen, D.G., Hayward, A.R., Reduced cellular immunity to varicella zoster virus during treatment for acute lymphoblastic leukemia of childhood: In vitro studies of possible mechanisms. J. Clin. Immunol. 6 (1986), 472–480.
31. Giller, R.H., Winistorfer, S., Grose, C., Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J. Infect. Dis. 160 (1989), 919–922.
32. Grose, C., Glycoproteins encoded by varicella-zoster virus: Biosynthesis, phosphorylation, and intracellular trafficking. Annu. Rev. Microbiol. 44 (1990), 59–80.
33. Hayward, A.R., T-cell responses to predicted amphipathic peptides of varicella-zoster virus glycoproteins II and IV. J. Virol. 64 (1990), 651–655.
34. Hayward, A.R., Herberger, M., Lymphocyte responses to varicella-zoster virus in the elderly. J. Clin. Immunol. 7 (1987), 174–178.
35. Hayward, A.R., Pontesilli, O., Herberger, O., Laszlo, M., Levin, M., Specific lysis of varicella zoster virus-infected B lymphoblasts by human T-cells. J. Virol. 58 (1986), 179–184.
36. Hayward, A.R., Burger, R., Schleper, T., Arvin, A.M., Major histocompatibility restriction of T-cell responses to varicella-zoster virus in guinea pigs. J. Virol. 65 (1991), 1491–1495.
37. Hickling, J.K., Borysiewicz, L.K., Sissons, J.G.P., Varicella-zoster virus specific cytotoxic T lymphocytes (Tc): Detection and frequency analysis of HLA class I-restricted Tc in human peripheral blood. J. Virol. 61 (1987), 3463–3469.
38. +T cells from young and old mice. J. Immunol. 150 (1993), 3602–3614.
39. +clones. J. Virol. 66 (1992), 2664–2669.
40. Kamiya, H., Ihara, T., Hattori, A., Iwasa, T., Sakurai, M., Izawa, T., Yamada, A., Takahashi, M., Diagnostic skin test reactions with varicella-zoster virus antigens and clinical application of the test. J. Infect. Dis. 136 (1979), 784–791.
41. Kinchington, P.R., Houghland, J., Arvin, A.M., Ruyechan, W., Hay, J., Varicella zoster virus IE62 protein is a major virion component. J. Virol. 66 (1992), 359–366.
42. Koropchak, C.M., Diaz, P.S., Arvin, A.M., Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. J. Virol. 63 (1989), 2392–2395.
43. Koropchak, C.M., Graham, G., Palmer, J., et al. Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J. Infect. Dis., 1991, 1016–1022.
44. Kundratitz, K., Experimentelle ubertrsgungen von herpes zoster auf menschen und die beriehungen von herpes zoster zu varizellen. Z. Kinderheilkd. 39 (1925), 379–387.
45. Levin, M.J., Murray, M., Rotbart, H.A., Zerbe, G.O., White, C.J., Hayward, A.F., The immune response of elderly individuals to a live attenuated varicella vaccine. J. Infect. Dis. 166 (1994), 253–259 1992.
46. Locksley, R.M., Flournoy, N., Sullivan, K.M., Meyers, J.D., Infection with varicella zoster virus after bone marrow transplantation. J. Infect. Dis. 152 (1985), 1172–1180.
47. Lowry, P.W., Solem, S., Watson, B.N., Koropchak, C.M., Thackray, H.M., Kinchington, P.R., Ruyechan, W.T., Ling, P., Hay, J., Arvin, A.M., Immunity in strain 2 guinea pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins, I, IV, V, or the protein product of the immediate early gene 62. J. Gen. Virol. 73 (1992), 811–819.
48. Lowry, P.W., Sabella, C., Koropchak, C.M., Watson, B.N., Thackray, H.M., Arvin, A.M., Investigation of the pathogenesis of varicella-zoster virus infection in guinea pigs using polymerase chain reaction. J. Infect. Dis. 167 (1992), 78–83.
49. Mahalingam, R., Wellish, M., Wolf, W., Dueland, A.N., Cohrs, R., Vafai, A., Gilden, D., Latent VZV DNA in human trigeminal and thoracic ganglia. N. Engl. J. Med. 323 (1990), 627–631.
50. Margalit, H., Spouge, J.L., Cornette, J.L., Cease, K.B., De Lisi, C., Berzofsky, J.A., Prediction of immunodominant helper T-cell antigenic sites from the primary sequence. J. Immunol., 138, 1987, 2213.
51. Meyers, J.D., Flournoy, N., Thomas, E.D., Cell-mediated immunity to varicella-zoster virus after allogeneic marrow transplant. J. Infect. Dis. 141 (1980), 479–487.
52. Miller, R.A., Aging and immune function. Int. Rev. Cytol. 124 (1991), 187–194.
53. +T-lymphocytes and epidermal cells in SCID-hu mice. J. Virol. 69 (1995), 5236–5242 1995.
54. Myers, M., Viremia caused by varicella-zoster virus: Association with malignant progressive varicella. J. Infect. Dis. 140 (1979), 229–232.
55. Myers, M.G., Stanbury, L.R., Edmond, B.J., Varicella-zoster virus infection of strain 2 guinea pigs. J. Infect. Dis. 151 (1985), 106–113.
56. Myers, M.G., Connelly, B.L., Stanberry, L.R., Varicella in hairless guinea pigs. J. Infect. Dis. 163 (1991), 746–751.
57. Nader, S., Bergen, R., Sharp, M., Arvin, A.M., Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J. Infect. Dis. 171 (1995), 13–17.
58. Namikawa, R., Kaneshima, H., Lieberman, M., Weissman, I.L., Mc Cune, J.M., Infection of the SCID-hu mouse by HIV-1. Science 242 (1988), 1684–1686.
59. Namikawa, R., Weilbaecher, K.M., Kaneshima, J., Yee, E.J., Mc Cune, J.M., Long term human hematopoiesis in the SCID-hu mouse. J. Exp. Med. 172 (1990), 1055–1063.
60. Ozaki, T., Ichikawa, T., Matsui, Y., Kondo, H., Nagai, T., Asano, Y., Yamanishi, K., Takahashi, M., Lymphocyte-associated viremia in varicella. J. Med. Virol. 19 (1986), 249–253.
61. Redman, R., Nader, S., Zerboni, L., Arvin, A.M., Evaluation of inactivated varicella vaccine in patients receiving bone marrow transplantation. Abstract Inter-science Conference on Antimicrobial Agents and Chemotherapy, San Francisco., 1995.
62. Rothbard, J.B., Taylor, W.R., A sequence pattern common to T cell epitopes. EMBO J., 7, 1988, 93.
63. Sabella, C., Lowry, P.W., Abbruzzi, G.M., Kinchington, P.R., Sadeghi-Zadeh, M., Ruyechan, W.T., Hay, J., Arvin, A.M., Immunization with the immediate early/tegument protein (ORF 62) of varicella-zoster virus protects guinea pigs against virus challenge. J. Virol. 67 (1993), 7673–7676.
64. Sawyer, M.H., Wu, Y.N., Chamberlin, C.J., et al. Detection of varicella-zoster virus DNA in the oropharynx and blood of patients with varicella. J. Infect. Dis. 166 (1992), 885–888.
65. −T cells and is restricted to the DR region of the MHC complex. J. Immunol. 140 (1986), 3610–3615.
66. Schrier, R.D., Gann, J.W. Jr., Landes, R., Lockshin, C., Richman, D., Mc Cutchan, A., Kennedy, C., Oldstone, M.B.A., Nelson, J.A., T cell recognition of HIV synthetic peptides in a natural infection. J. Immunol., 142, 1989, 1166.
67. Sharp, M., Terada, K., Wilson, A., Nader, S., Kinchington, P.E., Ruyechan, W., Hay, J., Arvin, A.M., The kinetics and protein specificity of T-lymphocyte cytotoxicity in healthy adults immunized with live attenuated varicella vaccine. J. Infect. Dis. 165 (1992), 852–858.
68. Shaw, S., Biddison, W.E., HLA-linked genetic control of the specificity of human cytotoxic T-cell responses to influenza virus. J. Exp. Med., 149, 1979, 565.
69. Straus, S., Reinhold, W., Smith, H., et al. Endonuclease analysis of viral DNA from varicella and subsequent zoster in the same patient. N. Engl. J. Med. 311 (1984), 1326–1328.
70. Thoman, M.L., Weigle, W.O., The cellular and subcellular bases of immunosenescence. Adv. Immunol. 46 (1989), 221–237.
71. +T-lymphocytes. J. Immunol. 142 (1989), 1325–1332.
72. Vafai, A., Wellish, M., Gilden, D.H., Expression of varicella-zoster virus DNA in blood mononuclear cells of patients with postherpetic neuralgia. Proc. Natl. Acad. Sci. U.S.A. 85 (1988), 2767–2770.
73. Watson, B., Keller, P.M., Ellis, R.W., Starr, S.E., Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: Kinetics and specificity. J. Infect. Dis. 162 (1990), 794–799.
74. Whitley, R.J., Varicella-zoster virus. Galasso, G., Whitley, R., Merigan, T.C., (eds.) ‘Antiviral Agents and Viral Diseases of Man’, 1990, Raven, New York, 235–264.
75. Wilson, A., Sharp, M., Koropchak, C.M., Ting, S.F., Arvin, A.M., Subclinical varicella-zoster virus viremia, herpes zoster and recovery of T-lymphocyte responses to varicella-zoster viral antigens after allogeneic and autologous bone marrow transplantation. J. Infect. Dis. 165 (1992), 119–126.